• OPEN AN ACCOUNT
Indian Indices
Nifty
24,363.30 -232.85
(-0.95%)
Sensex
79,857.79 -765.47
( -0.95%)
Bank Nifty
55,004.90 -516.25
( -0.93%)
Nifty IT
34,398.50 -328.30
( -0.95%)
Global Indices
Nasdaq
44,202.01 212.36
(0.48%)
Dow Jones
6,410.95 49.95
(0.79%)
Hang Seng
41,765.59 706.44
(1.72%)
Nikkei 225
9,095.73 -5.04
(-0.06%)
Forex
USD-INR
87.56 -0.16
(-0.18%)
EUR-INR
102.07 0.20
(0.20%)
GBP-INR
117.31 0.43
(0.37%)
JPY-INR
0.59 0.00
(-0.07%)

EQUITY - MARKET SCREENER

Venus Remedies Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
526953
INE411B01019
441.0060726
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VENUSREM
12.47
653.58
EPS(TTM)
Face Value()
Div & Yield %
39.2
10
0
 

ambica agarbathies aroma & industries ltd
Advait Energy Transitions rises on securing Rs 50-cr order from DGVCL
May 29,2025
As per the exchange filing, the turnkey contract involves the supply, installation, testing, and commissioning of 11 KV 55mm² AAAC Medium Voltage Covered Conductor (MVCC) along with its accessories. Notably, poles and associated fabrications required for the project will be provided by DGVCL.

The project, awarded under the Vanbandhu Kalyan Yojana (VKY-2) Scheme, is to be executed within a period of 15 months.

Advait Infratech is engaged in the business of providing products and solutions for power transmission, power substation, and telecommunication infrastructure fields. Also, it operates with various verticals such as turnkey telecommunication projects and installation of power transmission, substations, and telecom products.

The company’s consolidated net profit surged 78.14% to Rs 12.88 crore in Q4 FY25 as against Rs 7.23 crore posted in Q4 FY24. Revenue from operations zoomed 255.91% year on year to Rs 194.67 crore in the quarter ended 31 March 2025.